#UCB #bimekizumab #psoriaticarthritis #PsA #PsAbiologic #BEBOLDtrial #risankizumab #activepsoriaticarthritis #EULAR #biologics #headtoheadtrials #primaryendpoint #ACR50 #secondaryendpoints #diseaseactivity #inflammationcontrol #qualityoflife #headtoheadtrialdesign
zurl.co/htasR
zurl.co/htasR
UCB reports positive outcomes for bimekizumab in psoriatic arthritis - PharmaTimes
Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic
pharmatimes.com
May 20, 2026 at 8:45 AM
#Amgen #KyowaKirin #rocatinlimab #atopicdermatitis #phase3study #ASCENDstudy #Tcellrebalancingtherapy #OX40receptor #drugsafety #efficacy #ROCKETtrial #primaryendpoint #secondaryendpoints #HORIZONtrial #IGNITEtrial #rocatinlimabmonotherapy #OX40inhibition
pmlive.com/pharma_news/...
pmlive.com/pharma_news/...
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis - PMLiVE
The phase 3 study included around 2,600 patients
pmlive.com
September 23, 2025 at 8:23 AM
#ROMVIMZA #Vimseltinib #TGCTtreatment #tenosynovialgiantcelltumour #EU #symptomatictenosynovialgiantcelltumour #TGCT #marketingauthorisation #TGCTtherapy #OnoPharmaceutical #Deciphera #phase3MOTIONstudy #Secondaryendpoints #tumourresponse #stiffness #qualityoflife
pharmatimes.com/news/europea...
pharmatimes.com/news/europea...
European Commission approves ROMVIMZA for TGCT treatment - PharmaTimes
Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU
pharmatimes.com
September 22, 2025 at 8:26 AM